Abstracts tagged "Allopurinol"

Abstract Number: 3128 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Dual Energy Computed Tomography Study on the Effect of Urate Lowering Therapies on the Reduction of Tophus Burden in Patients with Chronic Gout
Hanna Ellmann¹, Sara Bayat¹, Isabelle Oliveira¹, Matthias Englbrecht^2,3, Elizabeth Araujo⁴, Alexander Cavallaro⁵, Silvana Mendonca⁶, Michael Lell⁵, Bernhard Manger², Georg Schett⁷ and Juergen Rech⁷, ¹Medical Department 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3; Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁵Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁶Americas Medical City, Rio de Janeiro, Brazil, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Dual energy computed tomography (DECT) allows reliably detecting and quantifying tophus burden in patients with chronic gout. Longitudinal studies on the effect of uric…
Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Jesse Hall¹, Michael Gillen², Xiaojuan Yang¹, Sha Liu¹, Susan Walker¹, Vicki Clauson¹ and Martin Kankam³, ¹Ardea Biosciences, Inc., San Diego, CA, ²AstraZeneca, Gaithersburg, MD, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…
Abstract Number: 196 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Allopurinol Versus Allopurinol Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Xiaohong Yan³, Jeffrey N. Miner^3,4, Liz Hicks³, Shakti Valdez³ and Martha Hernandez-Illas⁵, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ⁵QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 201 • 2016 ACR/ARHP Annual Meeting
Allopurinol Reduces the Risk of Myocardial Infarction (MI) in the Elderly: A Study of Medicare Claims
Jasvinder A. Singh¹ and Shaohua Yu², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess whether allopurinol use reduces the risk of myocardial infarction (MI) in the elderly. Methods: We used the 2006-2012 5% random sample of…
Abstract Number: 202 • 2016 ACR/ARHP Annual Meeting
Allopurinol Use and the Risk of Ventricular Tachycardia in the US Elderly: A Study of Medicare Claims Data
Jasvinder A. Singh¹ and John Cleveland², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of Alabama at Birmingham (UAB), Birmingham, AL
Background/Purpose: To assess whether allopurinol use reduces the risk of ventricular tachycardia in the elderly. Methods: We used the 2006-2012 5% random sample of Medicare…
Abstract Number: 203 • 2016 ACR/ARHP Annual Meeting
Allopurinol Dose Escalation and Mortality Among Patients with Gout: A National Propensity-Matched Cohort Study
Brian W Coburn^1,2, Kaleb Michaud³, Debra A Bergman² and Ted R Mikuls^4,5, ¹Research Service, Veterans Affairs Nebraska-Western Iowa Health Care System, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Allopurinol Dose Escalation and Mortality among Patients with Gout: A National Propensity-Matched Cohort Study Background/Purpose: Numerous epidemiologic studies show that hyperuricemia and gout are associated…
Abstract Number: 204 • 2016 ACR/ARHP Annual Meeting
The Safety and Efficacy of Allopurinol Dose Escalation in People with Gout, a Randomised Controlled Trial
Lisa K. Stamp¹, Peter T. Chapman², Murray Barclay³, Anne Horne⁴, Christopher Frampton¹, Paul Tan⁵, Jill Drake⁶ and Nicola Dalbeth⁵, ¹University of Otago, Christchurch, New Zealand, ²Christchurch Hospital, Christchurch, New Zealand, ³Medicine, University of Otago, Christchurch, New Zealand, ⁴Department of Medicine, University of Auckland, Auckland, New Zealand, ⁵University of Auckland, Auckland, New Zealand, ⁶Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
Background/Purpose: Allopurinol is the most widely used urate lowering therapy. Many patients on allopurinol fail to achieve target serum urate (SU), in part due to…
Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting
Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Michael A. Becker¹, Robert T. Keenan², Puja Khanna³, Raymond Malamet⁴, Kathleen Bos⁴, Jingyi Li⁴, Jia Hu⁵ and William White⁶, ¹University of Chicago, Chicago, IL, ²Rheumatology, Duke University, Durham, NC, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴AstraZeneca Pharmaceuticals, Wilmington, DE, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…
Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Kenneth Saag¹, Michael A. Becker², Chris Storgard³, Maple Fung³, Jia Hu³ and Thomas Bardin⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago, Chicago, IL, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Hôpital Lariboisière, Paris, France
Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…
Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Thomas Bardin¹, Nicola Dalbeth², Robert Terkeltaub³, Chris Storgard⁴, Maple Fung⁴, Jia Hu⁴ and Fernando Perez-Ruiz⁵, ¹Hôpital Lariboisière, Paris, France, ²University of Auckland, Auckland, New Zealand, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
Abstract Number: 210 • 2016 ACR/ARHP Annual Meeting
Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Neus Quilis¹, Mariano Andrés^1,2, Carlos Muñoz³, Paloma Vela^1,2 and Eliseo Pascual⁴, ¹Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain, ²Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain, ³Sección de Inmunología, Hospital General Universitario de Alicante, Alicante, Spain, ⁴Departamento de Medicina Clínica, Emeritus Professor, Universidad Miguel Hernández, Alicante, Spain
Background/Purpose: Allopurinol is the most used urate-lowering agent for patients with gout, but around 10% of patients show intolerance to this drug, often at skin,…
Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting
Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Stuart Katz⁴, Binita Shah⁵, Irina Dektiarev⁴, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, NYU School of Medicine, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁴Medicine/Cardiology, NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Division of Cardiology, New York, NY, ⁶Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
Abstract Number: 1230 • 2016 ACR/ARHP Annual Meeting
Allopurinol Use and the Risk of Stroke in the Elderly
Jasvinder A. Singh¹ and Shaohua Yu², ¹Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To assess the effect of allopurinol use on the risk of stroke in the elderly Methods: We used the 5% random sample of Medicare…
Abstract Number: 2240 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate: A Study Using Large Intergrated National Health Network
Jasvinder A. Singh¹, Shuo Yang², S. Louis Bridges Jr.³ and Kenneth G. Saag⁴, ¹Birmingham VAMC, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To comprehensively assess patient, comorbidity, physician, system, health care access and disease factors associated with the ability to achieve and maintain target serum urate…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].